The development of this draft Proposed programme budget 2022–2023 comes at a unique moment for WHO. The world is in the grip of the coronavirus disease (COVID-19) pandemic and faces health, social and economic consequences on an unprecedented scale. Although it is not known when the COVID-19 pande...mic will end, recent encouraging vaccine results, in addition to the examples of countries that have achieved good results through public health measures, hold out the prospect of better days ahead. The full impact of the pandemic cannot yet be determined. But whatever its implications, the Secretariat will rise to the challenge and is ready to adapt so that it is fully equipped to support Member States for any eventuality in the future – to make sure that the world will never again have to face this kind of crisis.
more
ПАКЕТ МЕР ПО РЕАЛИЗАЦИИ ПОЛИТИКИ В ОТНОШЕНИИ ВНЕДРЕНИЯ НОВЫХ ПРОТИВОТУБЕРКУЛЕЗНЫХ ПРЕПАРАТОВ
Lancet Infect Dis. 2019 Feb 21. pii: S1473-3099(18)30757-6. doi: 10.1016/S1473-3099(18)30757-6
This article is available free of charge.
Simply log in to access the full article, or register for free
An integrated approach to health and human rights lies at the heart of ensuring the dignity and well-being of women living with HIV.
Healthy me, healthy us: a guide for community members about good health and staying healthy with chronic illness
MOBILISIERUNG INLÄNDISCHER ÖFFENTLICHER RESSOURCEN FÜR GESUNDHEIT
Preventing Impairment & Disability
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
Q6: What is the added advantage of doing neuroimaging in people with convulsive epilepsy in non-specialist settings in low and middle income countries?